Fig. 1
From: Efficacy of galcanezumab in migraine central sensitization
Study design. The 1-month baseline period was followed by a 6-month treatment period. Galcanezumab (240 mg) was administered during the treatment period, followed by monthly subcutaneous injections of galcanezumab (120 mg).
